Abstract: Provided are methods and compositions directed to the treatment of an individual having cancer by (i) administering to the individual an adoptive cellular immunotherapy composition comprising CAR T cells and (ii) administering to the individual an interleukin-15 receptor agonist, such as, for example, a long-acting interleukin-15 receptor agonist.

Abstract: A specific binding molecule which binds to CD3 and comprises a polypeptide having an immunoglobulin VL domain and an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which (SEQ?ID?NO:?1) VLCDR1?is?QDIRNY VLCDR2?is?YTS (SEQ?ID?NO:?2) VLCDR3?is?QQGNTLPWT (SEQ?ID?NO:?3) VHCDR1?is?GYSFTGYA (SEQ?ID?NO:?4) VHCDR2?is?INPYKGVS (SEQ?ID?NO:?5) VHCDR3?is?ARSGYYGDSDWYFDV or an amino acid sequence at least 70% identical thereto.

Abstract: The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and methods of using these compositions, for example, for treating autoimmune diseases, and/or other conditions responsive to therapy that is effective to provide a selective increase in numbers and activation of regulatory T cells over effector T cells.

Abstract: The instant disclosure provides a long acting IL-15 receptor agonist, related compositions and methods of preparation and use, for example, in the treatment of conditions responsive to therapy effective to provide, for example, sustained immune activation and/or anti-tumor activity.

Abstract: Conjugates of an IL-7 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.

Abstract: In one or more embodiments of the invention, a method is provided, the method comprising the steps of administering to a cancer patient: (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a composition is provided, the composition comprising: an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a kit is provided, the kit comprising: an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; an IL-15R-activating amount of a long-acting, IL-15 moiety; and instructions for use of the IL-2R?-selective agonist and the long-acting, IL-15 moiety.

Abstract: Conjugates of an IL-15 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.